TG Therapeutics $TGTX is on the top$TGTX is hitting the 5 years high. It did %65 in this week so far. RSI is still 66 on weekly and needs more for breakout. It may pull back before continues
Biotechnology
Arrowhead Pharmaceuticals $ARWR $ARWR started to make HH and LH which is a good sign for an uptrend. Next it needs to break $40.19 and make ne HH at $46.58.
OGEN Long into and past earnings! Starting Today!AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday.
DD:
OGEN has
*1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15 Million worth of Warrants that will expire the day before. :) Also OGEN as obtained FDA Fast Track approval for this drug and marketing agreements completed in Europe to put it on the shelves immediately if Phase 2 data is good.
*1 drug for lowering cholesterol by 70% currently in Phase 1trial, expect results and Ph2 announcement mid/early summer.
*$21 Million cash on hand with burn rate of less than 10 Million per year.
*This Monday OGEN bought a COVID19 trial drug company with 4,000,000 shares or roughly $1 Million.
Trading in a channel, well established bases in this range over the last year or two, no need for extra funding for at least 1 year.
VBI vaccines $4 EOY Target Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020
Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020
Expanded immunologic, tumor, and clinical data from recurrent GBM Phase 2a clinical study of VBI-1901 expected mid-year and Q4 2020
Human proof-of-concept data from Phase 1b/2a study of hepatitis B immunotherapeutic, VBI-2601, expected H2 2020
Net cash proceeds of approximately $54 million added to balance sheet from underwritten public offering in April 2020
11 Million shares bought by insider www.sec.gov
Theravance Biopharma $TBPH support at 20SMAIt found it support at 20SMA and most likely will continue to rise
Pfizer and BioNTech Dose First Participants in the U.S. Hey fellow Traders from TradingView, this is an update to the actual Situation and my previous Analysis
If you agree with my Analysis or find it useful , please leave me a like for my work it would be greatly appreciated.
Im still bullish and optimistic that BNTX participation will have a huge global impact. The stock seems to be news related, so expect it to make huge moves when they finally will announce to have completed those first worldwide clinical studies.
The Moving Averages are lining up and signalizing us there will soon be a Price expansion.
Assuming the 55 MA line serves as a support we cacn expect the stock to bounce off that and rise to the resistance battleground area.
I´d place my Stop Loss below the next support pivot at either 36.85 to not risk gettiong shaken out before the upcoming outbreak. If you can handle that amount of risk.
If not a LOD SL is always a great way to reduce risk.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. This U.S. trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.
"The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates, and is to be evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S. will enroll up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with a given dose level of a vaccine candidate once testing of that candidate and dose level in younger adults has provided initial evidence of safety and immunogenicity. Sites currently dosing participants include NYU Grossman School of Medicine and the University of Maryland School of Medicine. The University of Rochester Medical Center/Rochester Regional Health and Cincinnati Children’s Hospital Medical Center will begin enrollment shortly."
Source by: NASDAQ:BNTX FWB:22UA investors.biontech.de
Remember, this is only my opinion after considering all facts and informing myself about the Up/Downside of this stock.
So no financial advise is given here. Always do your own reasearch.
Thank you for taking the time and i hope to see you again in my next post!
See you there
Sincerly,
Sebastian - TradingExperts Europe
$DVAX can rise in the next daysContextual immersion trading strategy idea.
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation.
The demand for shares of the company looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $3,94;
stop-loss — $3,80.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
BioMarin Pharmaceutical $BMRN. "Fake Breakout" ?It break out the pivot. Both the volume and RSI are weak. possible pull back to $92
Bullish Technical Setup provided by ALEC / Through 26NASDAQ:ALEC
Hey Guys, today i´d like to showcase you a sharp ooking Long Setup for a shorter time frame.
We are looking here at an uplifting and trending Bio TECH Stock that has shows previous Strenght when the market had its weakness.
Alector, Inc. operates as a clinical-stage biopharmaceutical company. They are developing therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease.
No real profits are yet achieved for the Company but it still has a solid looking balance sheet.
ALEC had a appropriate Consolidation Phase last week where it bounced back multiply times from the 26$ Resistance Level.
Looking at the Hourly the Stock set ups very well it its given Range
The Moving Averages dispaly that the Stock should be ready for a breakout expansion with a confirmation from high Volume following through.
My Entry would be at 26.10 to not get trapped.
Targets are 30, 32 and 36
I´d set my SL at LOD and then trail it with a 15min candel upwards to not give back any gains.
This is only my opinion on technical Analysis and not a buy or sell recommendations. Do your own research before jumping into a bandwagon.
Please leav me a like or a comment if you want to see more of my Analysis !
It would mean a lot to me and id´be greatly appreciated.
Thanks,
Sebastian - TradingExperts EU
MJ Trending UpETFMG Alternative Harvest (NYSE: MJ )
What is ETFMG Alternative Harvest?
An ETF that acceptance of various uses of the cannabis plant such as pharmaceuticals, biotechnology and life sciences,
JesusTrade Score:
Buy
Scale Score:
Low (3/10)
Portfolio Hold:
Yearly Hold
Fundamental Reasoning:
The following below are the top 10 holding for MJ:
GW Pharmaceuticals PLC Sponsored ADR (GWPH) Aphria Inc (APHA) Aurora Cannabis Inc. (ACB) MediPharm Labs Corp. (MEDIF)
Cronos Group Inc (CRON) Corbus Pharmaceuticals Holdings Inc (CRBP) OrganiGram Holdings Inc (OGI)
Canopy Growth Corporation (CGC) Tilray, Inc. (TLRY) Swedish Match AB (SWMAF)
All of these but Tilray and Swedish Match have bullish diverange and have broke out. Tilray could just follow the hype of the other stocks and Swedish Match has been having an up trend since March of 2009 and has about $30 more to run. With mojirty of these stocks being worth less than $10 or even $5. I don't see why the volume wouldn't be coming in. On google trends there an increase of cannabis and cannabis companies being searched. which gives me a idea that new buyers could be coming.
Exelixis $EXEL Monthly Outlook$EXEL run %54 so far on this month. It is very close to pivot. Expect to pull back to form the handle
Biontech AG Outbreak - First COVID-19 human vaccine trial test Hey fellow Trader,
The uprising Biotechnology company from NASDAQ:BNTX Mainz, Germany is on its final steps from developing a vaccine for the actual Bio-weapon health crisis from the "new flu" .
With Rolf Zinkernagel a brilliant Scientiests that can proudly say to win a nobelprice and a strong financial background , from big names in the Pharmaceutical field.
When BioNTech AG announced to start with the first human vaccine tests after getting an approval in Europa , a US approval should follow shortly after also.
We should expect News from those test in end May/june and if they´ve managed to create a proven vaccine afterwards im staying LONG in this Outbreak because its Trending and the Chances are high for a good R/R.
A Golden Cross is forming and the Overall Stock is positive and with a low beta so less correlation risk in this given "Crazy Market" .
So with a break of the 56 level we should see a strong move up.
Goals are high and i think it could touch the 100 mark again with reactive move down to given support levels if they arent successful with their vaccine Therapy.
STOPLOSS tight at 49,45
I hope this was helpful but it only displays my opionion and no financial adivce is given here.
Sincerly,
Sebastian
Alnylam Pharmaceuticals $ALNY#AlnylamPharmaceuticals just hit the strong resistance. Volume is above the average but RSI is below the trendline. Negative divergence is on weekly
MTNB - Bullish Weekly - Trade the Zones - Play the TicksI actually trade this for 15-20% gains on deep supply zones. Last time I got in was .51 so not bad if you understand where to buy in. I like the swings in this stock and has some volume. Bullish weekly at least to start off next week. Might fail right away with the resistance and the highs. Just need a solid open above .73. Still not banking on that. Just wanted to share a decent penny stock that if you know where to buy in then you can get some decent returns over and over. At least for now.
"Reasons Why Long-term Faith on Matinas BioPharma Holdings, Inc. (MTNB) Could Pay Off Investors"
investchronicle.com
Moderna $MRNA#Moderna is resting after break out. $36 is the critical resistance. watch for rsi and volume.
$MNOV can rise in the next daysContextual immersion trading strategy idea.
The demand for shares of MediciNova looks higher than the supply.
The company focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs.
Due to the spread of COVID-19, the demand for the company`s services rose.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $4,41;
stop-loss — $4,21.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Novavax $NVAX#Novavax hit the weekly 100SMA and stalling and forming double top. It may pull back on next week.
Moderna $MRNAModerna is one of the best pick for COVID-19 vaccine. They have already started dosing patients and expect the vaccine to be available for high-risk people like healthcare workers in the Fall this year.
The strength is rising and needs to close above $36 by the end of next week.
Seattle genetics $SGEN#SeattleGenetics is doing several impressive studies which helped stock price moved up.They stayed strong during the crash. It is doing well so far but it may stall for a while because of the coming resistances.
$AYTU can rise in the next daysContextual immersion trading strategy idea.
Aytu BioScience has a strong upward trend.
The company develops and commercializes novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility.
Due to the spread of the COVID-19, the demand for the company's services rose.
Today Aytu BioScience received confirmation from the FDA that it may begin distribution of its COVID-19 IgG/IgM Rapid Test throughout the U.S. — finance.yahoo.com
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $1,85;
stop-loss — $1,65.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
